|
Pronunciation |
|
(yu
RAP i
dil) |
|
|
U.S. Brand
Names |
|
Ebrantil®; Eupressyl®;
Uraprene® |
|
|
Synonyms |
|
Urapidil Hydrochloride |
|
|
Pharmacological Index |
|
Vasodilator |
|
|
Adverse
Reactions |
|
Cardiovascular: Palpitations, bradycardia, hypotension (orthostatic), sinus
bradycardia
Central nervous system: Headache, dizziness, fatigue
Dermatologic: Allergic skin reactions, pruritus
Gastrointestinal: Nausea
Renal: Enuresis
Respiratory: Nasal congestion |
|
|
Drug
Interactions |
|
Cimetidine modifies pharmacokinetics such that dosage reduction is
necessary |
|
|
Mechanism of
Action |
|
Alpha1-adrenoceptor antagonist (peripheral vasodilator); a
phenylpiperazine derivative of 4-aminouracil |
|
|
Pharmacodynamics/Kinetics |
|
Protein binding: 80%
Metabolism: Hepatic to p-hydroxylated urapidil - first pass (20%)
Bioavailability: 70%
Half-life:
Oral: 4.7 hours
I.V.: 2.7 hours
Elimination: Urine (15% to 30% unchanged) |
|
|
Usual Dosage |
|
Oral: 30-90 mg twice daily
I.V.: 25 mg over 20 seconds |
|
|
Reference Range |
|
Dose of 120 mg can cause a urapidil blood level of 750 ng/mL 3-5 hours
postingestion |
|
|
Additional
Information |
|
20% as potent as prazosin; may increase plasma renin and catecholamine
level |
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|